Drug‐induced pneumonitis risk in diffuse large B‐cell/follicular lymphoma patients treated with R‐CHOP‐like regimen is associated with the use of granulocyte colony‐stimulating growth factors

Documenti analoghi

• Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
  di: Minna Harmanen, et al.
  Pubblicazione: (2025)
• Socioeconomic Status and Access to Treatment in Diffuse Large B‐Cell Lymphoma
  di: Kuitunen Joonas, et al.
  Pubblicazione: (2026)
• Nodal peripheral T‐cell lymphoma in Finland between 2007 and 2019: Incidence, late morbidity and survival
  di: Anu Partanen, et al.
  Pubblicazione: (2025)
• Prolonged Time From Symptoms to Diagnosis Is Associated With an Inferior Progression‐Free Survival in Diffuse Large B‐Cell Lymphoma
  di: Susanna Tokola, et al.
  Pubblicazione: (2025)
• 299 | LOW SOCIOECONOMIC STATUS IS ASSOCIATED WITH AN INFERIOR PROGNOSIS IN DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS DESPITE THE AGE
  di: H. Kurttila, et al.
  Pubblicazione: (2025)